Registry collecting imaging data for patients with atrial fibrillation
Multimodal, Multicentre Registry of Clinical and Imaging Data to Develop Predictive Models Based on Artificial Intelligence to Support the Diagnostic and Therapeutic Process for Patients with Atrial Fibrillation Undergoing Catheter Ablation and Cardioversion.
This study is collecting imaging data from patients with atrial fibrillation to see if artificial intelligence can help predict blood clots in the heart before they undergo treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University in Zielona Góra Academic / other |
| Locations | 7 sites (Brno and 6 other locations) |
| Trial ID | NCT06584266 on ClinicalTrials.gov |
What this trial studies
This observational registry aims to gather a curated dataset of multimodal imaging data from patients with atrial fibrillation or flutter who undergo transesophageal echocardiography prior to catheter ablation or cardioversion. The study focuses on utilizing artificial intelligence to analyze transthoracic echocardiography video images combined with clinical data to predict the presence of left atrial appendage thrombus. By developing and validating an AI model, the study seeks to enhance risk prediction and outcomes for these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with atrial fibrillation or atrial flutter who are scheduled to undergo transesophageal echocardiography.
Not a fit: Patients under 18 years old or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction of thrombus presence, potentially reducing the risk of stroke in patients with atrial fibrillation.
How similar studies have performed: Other studies have shown promise in using AI for medical imaging analysis, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- All patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period (all consecutive patients). Exclusion Criteria: Age\<18, lack of informed, written consent to the TEE
Where this trial is running
Brno and 6 other locations
- St. Anne Hospital — Brno, Czechia (Not_yet_recruiting)
- Nowa Sol Multidyscyplinary Hospital — Nowa Sól, Lubusz Voivodeship, Poland (Recruiting)
- Medical University of Silesia — Katowice, Poland (Not_yet_recruiting)
- John Paul II Hospital — Krakow, Poland (Recruiting)
- Military Institute of Medicine National Research Institute — Warsaw, Poland (Recruiting)
- National Institute of Cardiology — Warsaw, Poland (Not_yet_recruiting)
- Collegium Medicum, University of Zielona Góra — Zielona Góra, Poland (Recruiting)
Study contacts
- Principal investigator: Konrad Pieszko, MD, PhD — University of Zielona Gora
- Study coordinator: Konrad Pieszko, MD, PhD
- Email: k.pieszko@cm.uz.zgora.pl
- Phone: +48728358082
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.